A Review on Recall and Ban of Ranitidine: Facts & Theories

Authors: Borade SA* and Bade AA

DOI: 10.23880/act-16000313

Volume 9, Issue 2

Abstract

The twentieth century witnessed the rise of peptic ulcers as a chronic illness affecting up to 10% of people worldwide. Initially thought to be caused solely by factors like stress and diet, the discovery of Helicobacter pylori bacteria by Robin Warren and Barry J. Marshall in 1982 revolutionized the understanding and treatment of peptic ulcers. This led to the development and widespread use of drugs like ranitidine, a histamine H2-receptor antagonist, which effectively reduced stomach acid production and provided relief from ulcer symptoms. However, recent concerns about ranitidine’s safety arose when elevated levels of the carcinogenic contaminant N-nitrosodimethylamine (NDMA) were found in some formulations. This prompted regulatory actions, including recalls, and raised questions about the long-term use of ranitidine and its potential health risks.

Keywords: Peptic Ulcer; Helicobacter Pylori; Ranitidine; Histamine H2-Receptor Antagonist; N-Nitrosodimethylamine (NDMA); Carcinogen; Drug Recall

View PDF